197 related articles for article (PubMed ID: 21095572)
1. Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.
Smith PA; Roberts TC; Romesberg FE
Chem Biol; 2010 Nov; 17(11):1223-31. PubMed ID: 21095572
[TBL] [Abstract][Full Text] [Related]
2. Initial efforts toward the optimization of arylomycins for antibiotic activity.
Roberts TC; Schallenberger MA; Liu J; Smith PA; Romesberg FE
J Med Chem; 2011 Jul; 54(14):4954-63. PubMed ID: 21630667
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci.
Smith PA; Powers ME; Roberts TC; Romesberg FE
Antimicrob Agents Chemother; 2011 Mar; 55(3):1130-4. PubMed ID: 21189343
[TBL] [Abstract][Full Text] [Related]
4. Type I signal peptidase and protein secretion in Staphylococcus aureus.
Schallenberger MA; Niessen S; Shao C; Fowler BJ; Romesberg FE
J Bacteriol; 2012 May; 194(10):2677-86. PubMed ID: 22447899
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Protein Secretion in
Walsh SI; Peters DS; Smith PA; Craney A; Dix MM; Cravatt BF; Romesberg FE
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420476
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition.
Smith PA; Romesberg FE
Antimicrob Agents Chemother; 2012 Oct; 56(10):5054-60. PubMed ID: 22802255
[TBL] [Abstract][Full Text] [Related]
7. Type I signal peptidase and protein secretion in Staphylococcus epidermidis.
Powers ME; Smith PA; Roberts TC; Fowler BJ; King CC; Trauger SA; Siuzdak G; Romesberg FE
J Bacteriol; 2011 Jan; 193(2):340-8. PubMed ID: 21075926
[TBL] [Abstract][Full Text] [Related]
8. Origins of Yersinia pestis sensitivity to the arylomycin antibiotics and the inhibition of type I signal peptidase.
Steed DB; Liu J; Wasbrough E; Miller L; Halasohoris S; Miller J; Somerville B; Hershfield JR; Romesberg FE
Antimicrob Agents Chemother; 2015 Jul; 59(7):3887-98. PubMed ID: 25896690
[TBL] [Abstract][Full Text] [Related]
9. [Novel inhibitors against the bacterial signal peptidase I].
Liao GJ; He Y; Xie JP
Yao Xue Xue Bao; 2012 Dec; 47(12):1561-6. PubMed ID: 23460958
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the type I signal peptidase as antibacterial target for biofilm-associated infections of Staphylococcus epidermidis.
Bockstael K; Geukens N; Van Mellaert L; Herdewijn P; Anné J; Van Aerschot A
Microbiology (Reading); 2009 Nov; 155(Pt 11):3719-3729. PubMed ID: 19696105
[TBL] [Abstract][Full Text] [Related]
11. A putative cro-like repressor contributes to arylomycin resistance in Staphylococcus aureus.
Craney A; Romesberg FE
Antimicrob Agents Chemother; 2015; 59(6):3066-74. PubMed ID: 25753642
[TBL] [Abstract][Full Text] [Related]
12. Crystallographic analysis of bacterial signal peptidase in ternary complex with arylomycin A2 and a beta-sultam inhibitor.
Luo C; Roussel P; Dreier J; Page MG; Paetzel M
Biochemistry; 2009 Sep; 48(38):8976-84. PubMed ID: 19655811
[TBL] [Abstract][Full Text] [Related]
13. Optimized arylomycins are a new class of Gram-negative antibiotics.
Smith PA; Koehler MFT; Girgis HS; Yan D; Chen Y; Chen Y; Crawford JJ; Durk MR; Higuchi RI; Kang J; Murray J; Paraselli P; Park S; Phung W; Quinn JG; Roberts TC; Rougé L; Schwarz JB; Skippington E; Wai J; Xu M; Yu Z; Zhang H; Tan MW; Heise CE
Nature; 2018 Sep; 561(7722):189-194. PubMed ID: 30209367
[TBL] [Abstract][Full Text] [Related]
14. A Putative Bacterial ABC Transporter Circumvents the Essentiality of Signal Peptidase.
Morisaki JH; Smith PA; Date SV; Kajihara KK; Truong CL; Modrusan Z; Yan D; Kang J; Xu M; Shah IM; Mintzer R; Kofoed EM; Cheung TK; Arnott D; Koehler MF; Heise CE; Brown EJ; Tan MW; Hazenbos WL
mBio; 2016 Sep; 7(5):. PubMed ID: 27601569
[TBL] [Abstract][Full Text] [Related]
15. Bacterial type I signal peptidase inhibitors - Optimized hits from nature.
Szałaj N; Benediktsdottir A; Rusin D; Karlén A; Mowbray SL; Więckowska A
Eur J Med Chem; 2022 Aug; 238():114490. PubMed ID: 35660251
[TBL] [Abstract][Full Text] [Related]
16. Not just an antibiotic target: Exploring the role of type I signal peptidase in bacterial virulence.
Walsh SI; Craney A; Romesberg FE
Bioorg Med Chem; 2016 Dec; 24(24):6370-6378. PubMed ID: 27769673
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of type I bacterial signal peptidase: Biological consequences and therapeutic potential.
Craney A; Romesberg FE
Bioorg Med Chem Lett; 2015 Nov; 25(21):4761-4766. PubMed ID: 26276537
[TBL] [Abstract][Full Text] [Related]
18. Initial Analysis of the Arylomycin D Antibiotics.
Tan YX; Peters DS; Walsh SI; Holcomb M; Santos-Martins D; Forli S; Romesberg FE
J Nat Prod; 2020 Jul; 83(7):2112-2121. PubMed ID: 32614583
[TBL] [Abstract][Full Text] [Related]
19. Efforts toward broadening the spectrum of arylomycin antibiotic activity.
Liu J; Smith PA; Steed DB; Romesberg F
Bioorg Med Chem Lett; 2013 Oct; 23(20):5654-9. PubMed ID: 24012184
[TBL] [Abstract][Full Text] [Related]
20. Single-molecule nanopore sequencing reveals extreme target copy number heterogeneity in arylomycin-resistant mutants.
Girgis HS; DuPai CD; Lund J; Reeder J; Guillory J; Durinck S; Liang Y; Kaminker J; Smith PA; Skippington E
Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
